GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vita Life Sciences Ltd (ASX:VLS) » Definitions » Return-on-Tangible-Equity

Vita Life Sciences (ASX:VLS) Return-on-Tangible-Equity : 17.69% (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Vita Life Sciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vita Life Sciences's annualized net income for the quarter that ended in Dec. 2024 was A$8.94 Mil. Vita Life Sciences's average shareholder tangible equity for the quarter that ended in Dec. 2024 was A$50.53 Mil. Therefore, Vita Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was 17.69%.

The historical rank and industry rank for Vita Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:

ASX:VLS' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.38   Med: 19.14   Max: 29.9
Current: 18.24

During the past 13 years, Vita Life Sciences's highest Return-on-Tangible-Equity was 29.90%. The lowest was 10.38%. And the median was 19.14%.

ASX:VLS's Return-on-Tangible-Equity is ranked better than
78.8% of 901 companies
in the Drug Manufacturers industry
Industry Median: 6.7 vs ASX:VLS: 18.24

Vita Life Sciences Return-on-Tangible-Equity Historical Data

The historical data trend for Vita Life Sciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vita Life Sciences Return-on-Tangible-Equity Chart

Vita Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.77 29.90 21.05 22.72 18.36

Vita Life Sciences Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.47 21.01 24.66 18.73 17.69

Competitive Comparison of Vita Life Sciences's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vita Life Sciences's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Vita Life Sciences's Return-on-Tangible-Equity falls into.


;
;

Vita Life Sciences Return-on-Tangible-Equity Calculation

Vita Life Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=8.784/( (43.371+52.304 )/ 2 )
=8.784/47.8375
=18.36 %

Vita Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=8.94/( (48.764+52.304)/ 2 )
=8.94/50.534
=17.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Vita Life Sciences  (ASX:VLS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Vita Life Sciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Vita Life Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Vita Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
Bath Road Kirrawee, Unit 1/ 102, Sydney, NSW, AUS, 2232
Vita Life Sciences Ltd is an Australian based pharmaceutical and healthcare company involved in formulating, packaging, sales, and distribution of vitamins and supplements. The company produces a wide range of premium supplements, vitamins, minerals, herbs and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold brands throughout Asia-Pacific region. The company has four reportable segments which include The Australia segment comprises of sale of Herbs of Gold range in Australia and exports into China. The Singapore and Malaysia segment, comprise of Vitahealth and Herbs of Gold range in both countries The other market segment comprises of Vitahealth ranges.

Vita Life Sciences Headlines

No Headlines